Aethlon Presents HIV-Treatment Device at XVI International AIDS Conference.

SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that the Hemopurifier(TM), a medical device developed to treat drug and vaccine resistant pathogens, was presented as a candidate treatment for drug resistant HIV patients at The AIDS Institute's Treatment Horizons Forum held in conjunction with the XVI International AIDS Conference in Toronto, Canada. The Treatment Horizons Forum provides the medical, scientific, and HIV-infected community the opportunity to learn about promising new developments in HIV/AIDS research. Aethlon Chairman and CEO James A. Joyce gave the presentation. Mr. Joyce has accepted a second invitation from The AIDS Institute to present at 8 pm EST this evening at the AIDS Global Village located in the Metro Toronto Convention Centre, host site of the XVI International AIDS Conference.

The presentation by Mr. Joyce highlighted the following:

--The Hemopurifier(TM) has been developed to address the treatment of drug and vaccine resistant pathogens, including HIV, the AIDS virus.

--The Hemopurifier(TM) is a medical device designed to mimic the natural immune response of clearing infectious viruses and toxins before the occurrence of cell and organ infection. Human in-vitro blood studies have documented a rapid capture of circulating HIV and gp120, a toxic surface protein known to deplete the immune T-cells required to fight off infection. If commercialized, the Hemopurifier(TM) would represent the first medical device enlisted as a treatment for HIV/AIDS.

--Aethlon researchers have immobilized affinity agents within the Hemopurifier(TM) that have been verified by the National Cancer Institute (NCI) and the National Institutes of Health (NIH) to have activity against all strains of HIV. By targeting the clearance of all HIV strains, including untreatable sub-species, the Hemopurifier(TM) provides treatment hope for the large and growing population of multiple drug resistant (MDR) patients. Mr. Joyce emphasized that the Hemopurifier(TM) is not a suitable treatment option for individuals still able to suppress viral load with antiretroviral (ARV) drug regimens.

--A recent human safety study in health-compromised individuals documented the application of twenty-four Hemopurifier(TM) treatments, each lasting four hours, without any material adverse events. The study, performed at The Apollo Hospital, in Delhi, India, enrolled patients afflicted with both kidney failure requiring dialysis, and advanced liver disease as a result of Hepatitis-C (HCV) infection. Aethlon also documented a significant capture of HCV (approximately 2 billion copies +/- 8.4%) in tested Hemopurifier cartridges.

--Aethlon plans to continue testing of the Hemopurifier(TM) in India, and has initiated discussions with the National Aids Research Institute (NARI), a government agency overseeing the 7.5 million HIV-infected patients in India, regarding a potential study to treat infected individuals in that country. The Company also confirmed it has filed a pre-IDE meeting submission with the Food and Drug Administration (FDA) to review a proposed clinical plan to test the Hemopurifier(TM) as a broad spectrum countermeasure against drug and vaccine resistant bioweapon threats, and pandemic influenza.

About The AIDS 2006 - XVI International AIDS Conference

AIDS 2006 is the landmark event for those concerned about the AIDS epidemic. The world's largest HIV/AIDS conference provides an international forum for the exchange of ideas, knowledge, and research that will strengthen HIV/AIDS prevention, treatment, and care efforts worldwide. An estimated 20,000 participants, including scientists, health care providers, government leaders, journalists, and people living with HIV/AIDS are expected. AIDS 2006 - XVI International AIDS Conference - August 13-18, 2006. Additional information can be found at www.aids2006.org.

About The AIDS Institute

The AIDS Institute (TAI) is a leading national public policy research, advocacy, and education agency with offices in Washington, DC, and Tampa, Florida, and is affiliated with The Division of Infectious Diseases and Tropical Medicine at the University of South Florida's College of Medicine. Additional information can be found at www.theaidsinstitute.org.

About Aethlon Medical

Aethlon Medical is developing the first medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets, including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Global researcher, Frost & Sullivan, recently awarded the Hemopurifier(TM) the 2006 Technology Innovation Award for its advances in the field of biodefense. Aethlon has also initiated research on a second-generation Hemopurifier(TM) that targets the capture of growth factors inherent in the spread of cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.